The early toxicity testing market accounted for $739 million in 2017, and is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.
The degree of threat posed by a chemical substance to the living organism is defined as toxicity. The branch of science that deals with measurement and further analysis of the adverse effects caused by these chemical substances on the body of an organism is called as toxicology. Toxicity testing of chemical substances is performed to select a potential drug candidate for development of newer molecules. Early toxicity is essential as it is the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Therefore, early toxicity testing is carried out at preclinical stages of a drug development process. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. There are different techniques such as in vivo, in vitro, and in silico that are employed for testing drug to monitor early toxicity associated with them. Different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others are performed using these techniques.
Major factors that drive the market growth are surge in the R&D activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in early toxicity testing industry across the globe, and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the global early toxicity testing market on the basis of technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.
On the basis of end user, the market is segmented into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Region wise, the market is studied across different regions such as North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Technique
By End User
By Region
o Canada
o Mexico
o France
o UK
o Rest of Europe
o China
o Japan
o Australia
o Rest of Asia-Pacific
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Major factors that drive the market growth are surge in the R&D activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in vitro techniques, rise in adoption of in vitro models in early toxicity testing industry across the globe, and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the global early toxicity testing market on the basis of technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.
On the basis of end user, the market is segmented into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Region wise, the market is studied across different regions such as North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Technique
- In Vivo
- In Vitro
- Enzyme Toxicity Assays
- Bacterial Toxicity Assays
- Cell-Based ELISA and Western Blots
- Tissue Culture Assays
- Receptor Binding Assays
- Other Assays
- Dermal Toxicity
- Systemic Toxicity
- Carcinogenicity
- Ocular Toxicity
- Skin Sensitization and Irritation
- Genotoxicity
- Neurotoxicity
- Organ Toxicity
- Other Toxicity Endpoints
By End User
- Pharmaceuticals Industry
- Food Industry
- Chemicals Industry
- Cosmetics Industry
- Other Industries
By Region
- North America
o Canada
o Mexico
- Europe
o France
o UK
o Rest of Europe
- Asia-Pacific
o China
o Japan
o Australia
o Rest of Asia-Pacific
- LAMEA
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Agilent Technologies, Inc.
- General Electric Company (GE Healthcare)
- Danaher Corporation (Beckman Coulter, Inc.)
- Evotec AG (Cyprotex)
- Bioanalytical Systems, Inc.
- Bruker Corporation
- Thermo Fisher Scientific, Inc.
- PerkinElmer Inc.
- Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
- Myriad Genetics, Inc. (Myriad RBM.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Randox Toxicology
- Geneva Laboratories, Inc.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
CHAPTER 6: EARLY TOXICITY TESTING MARKET, BY REGION
CHAPTER 7: COMPANY PROFILES
Executive Summary
According to this report titled,'Early toxicity testing Market by Technique and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,'the early toxicity testing market accounted for $739 million in 2017 is expected to reach $1,301 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.Early toxicity testing is analysis of new molecular entity during development process to obtain data related to the toxic effects of compound on body. Testing is performed to analyze the different type of unwanted effects produced by the compound in the body. These severe adverse drug reactions in the body can be circumvented with the use of early toxicity testing which makes it an important part of preclinical testing. The testing is carried out in different mediums such as in vivo, in vitro, and in silico. These tests are carried out before clinical trials to analyze the drug candidates, which are further tested in clinical studies carried out in humans.
Factors that drive the growth of the market include rise in R&D activities and surge in stringent regulatory authorities concerning public healthcare welfare. Increase in adoption of in vitro model which is the major current early toxicity testing market trend also boosts the growth of the market. However, challenges of preclinical testing hamper the market growth. Furthermore, technological advancements in preclinical diagnostic equipment provide lucrative opportunities for the early toxicity testing market growth.
On the basis of technique, the in vitro segment is a major revenue contributor in 2017 and is expected to maintain its dominant position throughout the analysis period due to rise in adoption of this technique across different diagnostic areas. Governments of different countries such as the U.S., the UK, Germany, and others are extensively active toward protection of animals. These countries have banned testing of cosmetic and household products on animals. Therefore, in vitro testing serves as a feasible alternative to in vivo testing, which also fuels the growth of the in vitro market. The in silico segment is expected to be the fastest growing segment during the forecast period, owing to rise in its adoption due to advantages offered by the technique such as determination of metabolic pathways of active molecules.
According to end users, the pharmaceutical industry segment accounted for the highest early toxicity testing market share in 2017, and is anticipated to maintain this trend over the forecast period, owing to rise in number of clinical trials for drug development. Cosmetics industry segment is the fastest growing segment during the forecast period owing to the stringent government regulations monitoring the assessment of chemicals incorporated in cosmetic products.
In 2017, Europe accounted for one-third of the total early toxicity testing market size and is expected to continue this trend owing to higher number of R&D activities, presence of research lab, companies and institutes, and wide availability of technologically advanced preclinical diagnostic instruments. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period.
Key Findings of the Early Toxicity Testing Market:
Pharmaceutical industry occupied two-thirds share of the market in 2017.
The in silico segment is anticipated to grow with the highest CAGR throughout the forecast period.
The in vitro segment accounted for half the share of the global early toxicity testing market in 2017.
The cosmetic segment is anticipated to grow at the highest rate during the analysis period.
The major companies profiled in this report include Agilent Technologies, Inc., General Electric Company (GE Healthcare), Danaher Corporation (Beckman Coulter, Inc.), Evotec AG (Cyprotex), Bioanalytical Systems, Inc., Bruker Corporation, Thermo Fisher Scientific, Inc., PerkinElmer Inc., Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.), and Myriad Genetics, Inc. (Myriad RBM.).
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
